Relmada Therapeutics is advancing REL-1017 for major depressive disorder (MDD), with interim analysis results expected by the end of 2024.

A novel hourglass-shaped stent demonstrates potential in alleviating angina for patients with microvascular disease, improving blood flow in small heart vessels.

BridgeBio's acoramidis shows positive Phase 3 results for ATTR-CM, with an FDA PDUFA date set for November 29, 2024, and potential $500M milestone payment upon approval.

Hoag Family Cancer Institute is participating in the LIBERATE study, which uses Focused Ultrasound to temporarily open the blood-brain barrier for liquid biopsies in glioblastoma patients.

The FDA granted accelerated approval to zanidatamab-hrii (Ziihera) for previously treated, unresectable or metastatic HER2-positive biliary tract cancer.

A gene therapy developed at Baylor College of Medicine, PCRX-201, is showing promising results in Phase 1 clinical trials for osteoarthritis.

CorMedix reported preliminary unaudited net revenue of approximately $31 million for Q4 2024 and $43 million for FY 2024, exceeding previous guidance.

OcuTerra Therapeutics' Phase 2 DR:EAM trial of nesvategrast eye drops did not meet its primary endpoint of improving DRSS scores in diabetic retinopathy patients.

Werewolf Therapeutics anticipates sharing preliminary monotherapy data for WTX-124 in H1 2025, potentially guiding regulatory engagement for accelerated approval.

Tarsus Pharmaceuticals is set to initiate a Phase 2 study of TP-04 (lotilaner ophthalmic gel) in the second half of 2025 for treating ocular rosacea.

Phase 3 C-POST trial reveals adjuvant Libtayo (cemiplimab) significantly improves disease-free survival (DFS) in high-risk cutaneous squamous cell carcinoma (CSCC) patients after surgery.

Be Bio has closed a $92 million Series C financing round to advance its B cell medicine (BCM) programs for hemophilia B and hypophosphatasia.

A Phase III trial of a higher 7.2 mg dose of Wegovy demonstrated a 20.7% weight loss over 72 weeks, compared to 17.5% with the standard 2.4 mg dose.

A real-world study demonstrates that eculizumab significantly reduces Myasthenia Gravis Activities of Daily Living (MG-ADL) scores in patients with thymoma-associated myasthenia gravis.

AIM ImmunoTech highlights the continued development of Ampligen (rintatolimod) across multiple clinical programs targeting pancreatic cancer and Long-COVID.

Becton Dickinson & Co. has filed a federal lawsuit against Baxter International Inc., claiming that Baxter's Novum IQ Infusion Platform infringes on six of BD's patents related to infusion-pump technologies.

Grace Therapeutics' Phase 3 STRIVE-ON trial of GTx-104, an injectable nimodipine formulation, met its primary endpoint with 19% reduction in clinically significant hypotension compared to oral nimodipine in aSAH patients.

Creative Medical Technology's CELZ-201 demonstrated significant reduction in insulin dependency and stable HbA1c levels in late-stage Type 2 diabetes patients over one year of treatment.

BioInvent International has secured FDA Fast Track Designation for BI-1808 in the treatment of relapsed or refractory mycosis fungoides and Sézary syndrome, two subtypes of cutaneous T-cell lymphoma.

Clinical trials imaging innovator Yunu has secured an oversubscribed investment round led by Spring Mountain Capital to accelerate pharma sponsor and site network growth.